Preview

Медицинский Совет

Расширенный поиск

Обзор сердечно-сосудистых рисков у пациентов с сахарным диабетом 2-го типа на фоне приема глибенкламида

https://doi.org/10.21518/2079-701X-2013-9-70-75

Полный текст:

Аннотация

Сахарный диабет 2-го типа — это хроническое, прогрессирующее заболевание, которое приводит к развитию специфических сосудистых осложнений: микроангиопатии и макроангиопатии. Данные осложнения являются причиной повышенной сердечно-сосудистой летальности больных с сахарным диабетом 2-го типа, в 4—5 раз превышающей этот показатель в общей популяции.

Об авторах

Н. А. Черникова
РМАПО
Россия


Е. А. Ермакова
РМАПО
Россия


Список литературы

1. UK Prospective Diabetes Study (UCPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compered with conventional treatment and risk of complications in patients with 1 diabetes (UKPDS) // Lancet. 1998. №352. Р. 837–853.

2. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. 2008. №358. Р. 2560–2572.

3. Kahn S.E., Zinman B., Lachin J.M. et al. (A Diabetes Outcome Progression Trial [ADOPT] Study Group). Rosiglitazone-associated fractures in type 2 diabetes:an analysis from A Diabetes Outcome Progression Trial (ADOPT) // Diabetes Care. 2008. №31. P. 845–851.

4. Pantalone K.M., Kattan M.W., Yu C., Wells B.J., Arrigain S., Jain A., Atreja A., Zimmerman R.S. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy. A retrospective analysis // Diabetes Care. 2010. №33. Р. 1224–1229.

5. Schramm T.K., Gislason G.H., Vaag A. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study // Eur. Heart J. 2011. №32. Р. 1900–1908.

6. Kristiansen S.B., Lofgren B., Nielsen J.M. et al. Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes. Diabetologia. 2011. №54. Р. 451–458.

7. Loubani M., Fowler A., Standen N.B., Galinanes M. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium // Eur. J. Pharmacol. 2005. №515. Р. 142–149.

8. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Meier J.J., Deifuss S., Klamann A., Launhardt V., Schmiegel W.H., Nauck M.A. // Diabetes Care. 2005. Oct. №28(10). Р. 2551–2553. No abstract available.

9. Lomuscio A. et al. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction // Coronary Artery Disease. 1994. Vol. 5. P. 767–771.

10. Davis T.M. et al. A rrhythmias and Mortality After Myocardial Infarction in Diabetic Patients // Diabetes Care. 1998. Vol. 21. №4. P. 637–640.

11. Gangji A.S., Cukierman T., Gerstain H.C., Goldsmith C.H., Clase C.M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. A comparison of glyburide with other secretagogues and with insulin // Diabetes Care. 2007. №30. P. 389–394.

12. Holstein A., Plaschke A., Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide // Diabetes Metab. Res. Rev. 2001. Vol. 17. №6. P. 467–473.

13. Chen M., Simard J.M. Cell swelling and a nonselective cation channel regulated by internal Ca2 and ATP in native reactive astrocytes from adult rat brain // J. Neurosci. 2001. Vol. 21. P. 6512–6521.

14. Chen M., Dong Y., Simard J.M. Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain // J. Neurosci. 2003. Vol. 23. P. 8568–8577.

15. Simard J.M., Chen M., Tarasov K.V. et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke // Nat. Med. 2006. Vol. 12. P. 433–440.

16. Chen M., Simard J.M. Cell swelling and a nonselective cation channel regulated by internal Ca2 and ATP in native reactive astrocytes from adult rat brain // J. Neurosci. 2001. Vol. 21. P. 6512–6521.

17. Chen M., Simard J.M. Cell swelling and a nonselective cation channel regulated by internal Ca2 and ATP in native reactive astrocytes from adult rat brain // J. Neurosci. 2001. Vol. 21. P. 6512–6521.

18. Kunte H. et al. Sulfonylureas Improve outcomes in patients with Type 2 diabetes and acute ischemic stroke // Stroke. 2007. Vol. 38. P. 2526–2530.

19. Kunte H., Busch M.A., Trostdorf K., Vollnberg B., Harms L., Mehta R.I., Castellani R.J., Mandava P., Kent T.A., Simard J.M. Hemorrhagic ransformation of ischemic stroke in diabetics on sulfonylureas // Ann. Neurol. 2012. Nov. №72(5). Р. 799–806. doi: 10.1002/ana.23680.

20. Kahn S.E., Haffner S.M., Heise M.A. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy // N. Engl. J. Med. 2006. №355(23). Р. 2427–2443.

21. Davidson J.A., Scheen A.J., Howlett H.C.Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus // Drug Saf. 2004. №27(15). Р. 1205–1216.

22. Gangi A.S., Cukierman T., Gestain H.C., Goldsmith C.H. Clase C.M. A systematic review and meta-analisis of hypoglycaemia and cardiovascular events. A comprasion of gliburide with other secretagogues and with insulin // Diabetes Care. 2007. №30. P. 389–394.

23. Charca A.R., Tan G.H., Aponovitch A. et.al Saxagliptin added to a submaximal dose of sulfonylurea improves glycaemic control compared with uptitration of sulfonylurea in patients with type 2 diabetes: a randomized controlled trial // Int. J. Clin. Pract. 2009. №63. P.1395–1406.

24. Serra D., He Y.L., Bullock J., Riviere G.J., Balez S., Schwartz S., Wang Y. Evaluation of pharmacokinetic and pharmakodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes // Int. J. Clin. Pharmacol Ther. 2008. №46. P. 349–364.


Для цитирования:


Черникова Н.А., Ермакова Е.А. Обзор сердечно-сосудистых рисков у пациентов с сахарным диабетом 2-го типа на фоне приема глибенкламида. Медицинский Совет. 2013;(9):70-75. https://doi.org/10.21518/2079-701X-2013-9-70-75

For citation:


Chernikova N.A., Ermakova E.A. Аn overview of cardiovascular risks in patients with type 2 diabetes receiving glibenclamide. Medical Council. 2013;(9):70-75. (In Russ.) https://doi.org/10.21518/2079-701X-2013-9-70-75

Просмотров: 74


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)